Narwhal Capital Management trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 1.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 183,597 shares of the biopharmaceutical company’s stock after selling 2,550 shares during the quarter. Pfizer makes up approximately 2.0% of Narwhal Capital Management’s holdings, making the stock its 9th largest position. Narwhal Capital Management’s holdings in Pfizer were worth $8,014,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of PFE. Family Management Corp boosted its position in Pfizer by 49.8% during the second quarter. Family Management Corp now owns 20,507 shares of the biopharmaceutical company’s stock worth $744,000 after purchasing an additional 6,820 shares during the period. Argent Trust Co boosted its position in Pfizer by 493.9% during the second quarter. Argent Trust Co now owns 237,713 shares of the biopharmaceutical company’s stock worth $8,625,000 after purchasing an additional 197,684 shares during the period. Lake Street Advisors Group LLC boosted its position in Pfizer by 61.3% during the second quarter. Lake Street Advisors Group LLC now owns 69,946 shares of the biopharmaceutical company’s stock worth $2,538,000 after purchasing an additional 26,575 shares during the period. Glenmede Trust Co. NA boosted its position in Pfizer by 5.4% during the second quarter. Glenmede Trust Co. NA now owns 3,307,190 shares of the biopharmaceutical company’s stock worth $119,984,000 after purchasing an additional 168,129 shares during the period. Finally, Davy Asset Management Ltd bought a new stake in Pfizer during the second quarter worth approximately $10,121,000. 69.49% of the stock is currently owned by institutional investors and hedge funds.
Shares of NYSE PFE traded up $0.24 during trading hours on Thursday, reaching $39.61. The stock had a trading volume of 16,924,903 shares, compared to its average volume of 24,567,809. The company has a current ratio of 1.57, a quick ratio of 1.33 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $234.57 billion, a price-to-earnings ratio of 13.20, a PEG ratio of 2.38 and a beta of 0.75. Pfizer Inc. has a twelve month low of $34.37 and a twelve month high of $46.47.
The company also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 10th will be paid a $0.36 dividend. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.64%. Pfizer’s payout ratio is 48.00%.
In other Pfizer news, insider Rady A. Johnson sold 8,700 shares of the stock in a transaction on Friday, March 15th. The stock was sold at an average price of $41.13, for a total transaction of $357,831.00. Following the completion of the transaction, the insider now directly owns 59,797 shares in the company, valued at $2,459,450.61. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Alexander R. Mackenzie sold 15,000 shares of the stock in a transaction on Monday, April 1st. The stock was sold at an average price of $42.83, for a total value of $642,450.00. Following the transaction, the insider now owns 124,994 shares of the company’s stock, valued at $5,353,493.02. The disclosure for this sale can be found here. Insiders sold 332,526 shares of company stock valued at $14,346,539 over the last 90 days. 0.09% of the stock is currently owned by corporate insiders.
A number of equities research analysts have issued reports on PFE shares. Bank of America upped their target price on Pfizer from $45.00 to $48.00 and gave the stock a “buy” rating in a research report on Monday, April 1st. Cantor Fitzgerald reaffirmed a “buy” rating and set a $53.00 target price on shares of Pfizer in a research report on Tuesday, February 19th. Argus raised Pfizer from a “hold” rating to a “buy” rating and set a $55.00 target price for the company in a research report on Thursday, January 31st. ValuEngine lowered Pfizer from a “buy” rating to a “hold” rating in a report on Thursday, January 24th. Finally, Zacks Investment Research upgraded Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, April 3rd. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and seven have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $45.61.
COPYRIGHT VIOLATION NOTICE: “Narwhal Capital Management Reduces Stake in Pfizer Inc. (NYSE:PFE)” was published by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://www.baseballdailydigest.com/news/2019/04/26/narwhal-capital-management-has-8-01-million-stake-in-pfizer-inc-pfe.html.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Read More: What is a Reverse Stock Split?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.